CURE Global X S&P Biotech ETF
- 47.010
- 0.0000.00%
13 Analysts Have This To Say About AbbVie
Behind the Scenes of Amgen's Latest Options Trends
Gilead Sciences Analyst Ratings
Live Stock News: -2.8% GDP, Trade War Sends Market Lower, Tesla Sales Punished
AbbVie Analyst Ratings
$1000 Invested In This Stock 5 Years Ago Would Be Worth This Much Today
AbbVie Announces SKYRIZI Available In Canada For Treatment Of Ulcerative Colitis Following Health Canada Approval
Natera Receives New Patent Related To Testing Of Single Nucleotide Variants In Circulating-Tumor DNA
Navigating a Sluggish Market: Building a Defensive Dividend Portfolio for Steady Passive Income
AbbVie Becomes Another Big Pharma To Enter Obesity Treatment Race
Amgen-AstraZeneca Partnered Asthma Drug Shows Rapid And Sustained Effect In Chronic Rhinosinusitis
Live Stock News: Chips Falling Alongside Crypto Despite Trump Money News-- the Honeymoon is Over
Reported Saturday, Amgen And AstraZeneca TEZSPIRE Phase III Trial Confirms Rapid And Lasting Relief In Nasal Polyps, Cutting Surgery Risk By 98%
AbbVie Enters Obesity Market With ~$2.2B Gubra Deal To Develop Next-Gen Amylin Therapy, With $350M Upfront Payment
Play Defense With Goldman's Cheap Healthcare Picks
S&P 500 February Winners, Losers as Stock Benchmark Ends Monthly Journey in the Red
Wall Street Today: Market Ends Wild Political TV Day in the Green
First Trust's New Small-Cap ETF Aims To Combine Growth With Income
AbbVie's RINVOQ Gains CHMP Backing For Giant Cell Arteritis, EU Decision Expected In H1 2025
Earnings Call Summary | Natera(NTRA.US) Q4 2024 Earnings Conference